ARTICLE | Clinical News
NicErase-SL sublingual: Will start a pilot Phase III trial
October 10, 1994 7:00 AM UTC
DynaGen Inc. (DYGN), Cambridge, Mass. Product: NicErase-SL sublingual Indication: Smoking cessation Status: Will start a pilot Phase III trial in 180 subjects who will self-administer the treatment f...